Table 5.
Therapy and outcome of MIS-C cohort respective of age.
| All (274) | 0–5 y.o. (64) | 5–12 y.o. (140) | 12–18 y.o. (70) | P | P|Sex | |
|---|---|---|---|---|---|---|
| Admission since onset (days) | 5.0 (4.0–6.0) | 5.0 (4.0–5.0) | 5.0 (4.0–6.0) | 5.0 (4.0–6.5) | 0.5 | 0.6 |
| Intensive care | 23 (8%) | 1 (2%) | 13 (9%) | 9 (13%) | 0.05 | 0.07 |
| Mechanical ventilation | 10 (4%) | – | 7 (5%) | 3 (5%) | 0.2 | 0.2 |
| Oxygen supplementation | 61 (23%) | 5 (8%) | 41 (31%) | 15 (23%) | < 0.01 | < 0.01 |
| No immunomodulatory agent | 8 (3%) | 3 (5%) | 3 (2%) | 2 (3%) | 0.6 | 0.4 |
| IVIG | 238 (93%) | 55 (90%) | 122 (95%) | 61 (91%) | 0.3 | 0.3 |
| GCS | 143 (67%) | 27 (56%) | 74 (69%) | 42 (71%) | 0.2 | 0.2 |
| IVIG and GCS | 133 (62%) | 24 (50%) | 69 (65%) | 40 (67%) | 0.1 | 0.2 |
| Any other immunomodulator | ||||||
| Tocilizumab | 1 (0%) | 1 (2%) | – | – | 0.2 | 0.1 |
| Cyclosporin A | 2 (1%) | – | 2 (1%) | – | 0.4 | 0.3 |
| ASA | 226 (85%) | 51 (81%) | 119 (88%) | 56 (84%) | 0.4 | 0.4 |
| Heparin | 91 (38%) | 14 (25%) | 45 (38%) | 32 (49%) | 0.02 | 0.02 |
| Warfarin | 1 (0%) | 1 (2%) | – | – | 0.2 | 0.1 |
| Complete recovery at discharge | 218 (93%) | 55 (95%) | 115 (94%) | 48 (87%) | 0.2 | 0.2 |
Binary data given as count (per-cent), and numerical data as median (interquartile range).
ASA acetylsalicylic acid, GCS glucocorticoids, IVIG intravenous immunoglobulin, y.o. years old, P|Sex sex-adjusted p-value.
*All signs and symptoms resolved at discharge.